Oncology runs clinical research, and the registry proves it

If you are deciding what to specialize in, or wondering why the oncology CRAs seem to have more leverage than everyone else, the trial registry settles it. We counted recruiting trials by therapeutic area, and one area towers over the rest. Where the trials are is where the careers are, and cancer is where the trials are.

The count

Recruiting trials by broad therapeutic area, from the public registry:

• Cancer and oncology: about 19,400
• Cardiovascular: about 9,800
• Women's health: about 5,300
• Respiratory: about 5,100
• Infectious disease: about 4,200
• Pediatric: about 4,200
• Mental health: about 2,600
• Neurology and CNS: about 2,300
• Diabetes: about 2,000
• Obesity: about 1,600
• Autoimmune and inflammatory: about 1,200
• Rare disease: about 240

Cancer outnumbers the second-largest area, cardiovascular, by roughly two to one, and it is close to a third of all recruiting trials where a therapeutic area is identifiable. No other area comes near it. These are keyword-based buckets and conditions overlap, so read the exact figures as directional, but the ranking is not close and not in doubt.

Why the concentration matters for pay

Specialization value follows trial volume. Oncology is complex, protocol-heavy, and relentless in its pipeline, which means the skill of monitoring or analyzing a cancer trial is both hard to acquire and constantly in demand. That combination is exactly what creates negotiating leverage. An oncology CRA can move between sponsors and CROs more easily than a generalist, because there is always another oncology program that needs someone who has done it before.

The same logic runs through the quantitative functions. Oncology biostatisticians and programmers work with the most demanding endpoints and the deepest pipeline, and they are compensated for scarcity in a high-demand area. When our salaries page fills in with real datapoints, the therapeutic-area premium is one of the first patterns worth watching, and oncology is the obvious place to expect it.

The trade-off nobody mentions

Concentration cuts both ways. Oncology trials are the hardest work in clinical research: the sickest patients, the most complex safety reporting, the heaviest monitoring load. The leverage is real, and so is the burnout risk. Choosing oncology for the career mobility means choosing the workload that comes with it. That is a fair trade for many people, but it should be an informed one.

What the registry cannot price

The registry tells you where the trials are. It cannot tell you what an oncology CRA actually clears versus a generalist, or whether the specialization premium is 5 percent or 25 percent, because pay is not in the trial record. That gap, the dollar value of specializing, is exactly what the salary survey is built to measure, and it is the one number that would let someone decide whether the oncology grind pays for itself. If you work in a therapeutic area, add your datapoint. The registry shows where the work concentrates. Only you can show what it pays.